Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma

•VTE developed in 11% of lymphoma patients after CAR T-cell therapy and was managed safely with anticoagulation.•Coagulation abnormalities after CAR T-cell therapy occur but do not commonly lead to bleeding events. [Display omitted]

Saved in:
Bibliographic Details
Published in:Blood advances 2020-09, Vol.4 (17), p.4086-4090
Main Authors: Hashmi, Hamza, Mirza, Abu-Sayeef, Darwin, Alicia, Logothetis, Constantine, Garcia, Franco, Kommalapati, Anuhya, Mhaskar, Rahul S., Bachmeier, Christina, Chavez, Julio C., Shah, Bijal, Pinilla-Ibarz, Javier, Khimani, Farhad, Lazaryan, Aleksandr, Liu, Hien, Davila, Marco L., Locke, Frederick L., Nishihori, Taiga, Jain, Michael D.
Format: Article
Language:English
Subjects:
Antigens, CD19
Humans
Immunotherapy, Adoptive
Lymphoma, Large B-Cell, Diffuse - therapy
Receptors, Antigen, T-Cell
Stimulus Report
Venous Thromboembolism - etiology
Venous Thromboembolism - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•VTE developed in 11% of lymphoma patients after CAR T-cell therapy and was managed safely with anticoagulation.•Coagulation abnormalities after CAR T-cell therapy occur but do not commonly lead to bleeding events. [Display omitted]
ISSN:2473-9529
2473-9537
DOI:10.1182/bloodadvances.2020002060